Drug intelligence / Profile preview

ALN1002

Development stage: Preclinical
Lead developer: Alaunos Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ALN1002 is a preclinical-stage, non-hormonal small molecule being developed by Alaunos Therapeutics for the treatment of obesity. While Alaunos has historically focused on TCR-T cell therapies for oncology, ALN1002 represents an expansion into metabolic diseases. The drug is designed for oral administration and targets an undisclosed mechanism of action distinct from traditional hormonal pathways (such as GLP-1). As of early 2025, the program remains in the preclinical phase of development.

Beyond the preview

Go deeper on ALN1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALN1002.

Explore the full profile